OBJECTIVE: To assess the incidence of skin scarring and orthopaedic sequelae (amputation, limb-length discrepancy) in patients who survived meningococcal septic shock (MSS) in childhood and to determine the severity and predictors of these sequelae. METHODS: 179 consecutive patients (170 of whom were eligible) with septic shock and purpura requiring intensive care between 1988 and 2001 in Rotterdam, the Netherlands were invited to visit a follow-up clinic 4-16 years after paediatric intensive care unit (PICU) discharge. RESULTS: 58 (48%) of 120 follow-up patients (median follow-up interval 10 years; median age at follow-up 14.5 years) had skin scarring due to purpura. This varied from barely visible to extremely disfiguring scars. Ten patients (8%) had undergone amputation(s) of extremities, ranging from one toe to both legs and one arm. Seven patients (6%) had lower limb-length discrepancy, in most cases together with angular deformity, requiring one or more late surgical intervention(s). Patients with scars or orthopaedic sequelae had significantly higher severity of illness scores, determined by the Pediatric Risk of Mortality score, Vasopressor score and Disseminated Intravascular Coagulation score. Gender or Neisseria meningitidis serogroup had no significant influence on the presence of scars or orthopaedic sequelae. Patients with lower limb-length discrepancy were significantly younger at the time of PICU admission. CONCLUSIONS: The incidence of long-term skin scarring and orthopaedic sequelae was high (48% and 14%, respectively) in patients who survived MSS in childhood. The severity of these sequelae varied from mild to severe. Patients with scars or orthopaedic sequelae had significantly higher severity of illness scores.
OBJECTIVE: To assess the incidence of skin scarring and orthopaedic sequelae (amputation, limb-length discrepancy) in patients who survived meningococcal septic shock (MSS) in childhood and to determine the severity and predictors of these sequelae. METHODS: 179 consecutive patients (170 of whom were eligible) with septic shock and purpura requiring intensive care between 1988 and 2001 in Rotterdam, the Netherlands were invited to visit a follow-up clinic 4-16 years after paediatric intensive care unit (PICU) discharge. RESULTS: 58 (48%) of 120 follow-up patients (median follow-up interval 10 years; median age at follow-up 14.5 years) had skin scarring due to purpura. This varied from barely visible to extremely disfiguring scars. Ten patients (8%) had undergone amputation(s) of extremities, ranging from one toe to both legs and one arm. Seven patients (6%) had lower limb-length discrepancy, in most cases together with angular deformity, requiring one or more late surgical intervention(s). Patients with scars or orthopaedic sequelae had significantly higher severity of illness scores, determined by the Pediatric Risk of Mortality score, Vasopressor score and Disseminated Intravascular Coagulation score. Gender or Neisseria meningitidis serogroup had no significant influence on the presence of scars or orthopaedic sequelae. Patients with lower limb-length discrepancy were significantly younger at the time of PICU admission. CONCLUSIONS: The incidence of long-term skin scarring and orthopaedic sequelae was high (48% and 14%, respectively) in patients who survived MSS in childhood. The severity of these sequelae varied from mild to severe. Patients with scars or orthopaedic sequelae had significantly higher severity of illness scores.
Authors: Manish Sadarangani; Tim Sell; Mildred A Iro; Matthew D Snape; Merryn Voysey; Adam Finn; Paul T Heath; Gianni Bona; Susanna Esposito; Javier Diez-Domingo; Roman Prymula; Adefowope Odueyungbo; Daniela Toneatto; Andrew J Pollard Journal: CMAJ Date: 2017-10-16 Impact factor: 8.262
Authors: Alex Veldman; Doris Fischer; Flora Y Wong; Wolfhart Kreuz; Michael Sasse; Bruno Eberspächer; Ulrich Mansmann; Rudolf Schosser Journal: Crit Care Date: 2010-08-19 Impact factor: 9.097
Authors: Corinne M P Buysse; Lindy C A C Vermunt; Hein Raat; Jan A Hazelzet; Wim C J Hop; Elisabeth M W J Utens; Koen F M Joosten Journal: Crit Care Date: 2010-06-29 Impact factor: 9.097
Authors: Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma Journal: Hum Vaccin Immunother Date: 2013-02-13 Impact factor: 3.452
Authors: Daniël Bossen; Rosa M de Boer; Hendrika Knoester; Jolanda M Maaskant; Marike van der Schaaf; Mattijs W Alsem; Reinoud J B J Gemke; Job B M van Woensel; Jaap Oosterlaan; Raoul H H Engelbert Journal: Crit Care Explor Date: 2021-06-15